Shom Goel

List of Publications by Year
in descending order

54 papers	6,528 citations	159358 30 h-index	223531 46 g-index
54 all docs	54 docs citations	54 times ranked	11206 citing authors

#	Article	IF	Citations
1	Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study. Cancer Research, 2022, 82, OT2-19-01-OT2-19-01.	0.4	0
2	Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Research, 2022, 24, 17.	2.2	45
3	Targeting CDK4 and CDK6 in cancer. Nature Reviews Cancer, 2022, 22, 356-372.	12.8	125
4	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer, 2021, 2, 34-48.	5.7	48
5	Transforming growth factor Î² in breast cancer: another new trick for the old dog. Immunology and Cell Biology, 2021, 99, 249-251.	1.0	1
6	Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. Translational Oncology, 2021, 14, 100939.	1.7	18
7	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discovery, 2021, 11, 2564-2581.	7.7	58
8	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 103.	2.3	17
9	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
10	Trastuzumab-related cardiotoxicity: what do we know in 2020?. Translational Cancer Research, 2020, 9, 4052-4055.	0.4	0
11	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	2.3	90
12	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
13	Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. The Cochrane Library, 2020, 3, CD013538.	1.5	23
14	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 763-775.	5.1	144
15	Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+) Tj ETQq1 1 0.784314 rgBT /Overlo		
16	Decline in Left Ventricular Ejection Fraction Following Anthracyclines PredictsÂTrastuzumab Cardiotoxicity. JACC: Heart Failure, 2019, 7, 795-804.	1.9	28
17	CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?. Lancet Oncology, The, 2019, 20, 1479-1481.	5.1	7
18	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer, 2019, 19, 399-404.	1.1	27

#	Article	IF	Citations
19	CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878645.	1.4	218
20	CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends in Cell Biology, 2018, 28, 911-925.	3.6	273
21	An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. ELife, 2018, 7, .	2.8	91
22	CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. Current Breast Cancer Reports, 2017, 9, 26-33.	0.5	55
23	Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell, 2017, 31, 576-590.e8.	7.7	84
24	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine, 2017, 9, .	5.8	89
25	CDK4/6 inhibition triggers anti-tumour immunity. Nature, 2017, 548, 471-475.	13.7	998
26	Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cellâ€“Mediated Immunotherapy. Cancer Research, 2017, 77, 4434-4447.	0.4	52
27	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine, 2016, 22, 723-726.	15.2	105
28	PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. Annals of Oncology, 2016, 27, 1368-1372.	0.6	17
29	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 2016, 29, 255-269.	7.7	356
30	CDK4/6 inhibition: the late harvest cycle begins. Oncotarget, 2016, 7, 48854-48856.	0.8	4
31	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14325-14330.	3.3	206
32	Optimizing the Management of Metastatic HER2-Positive Breast Cancer. Current Breast Cancer Reports, 2015, 7, 190-202.	0.5	0
33	Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	106
34	Adjuvant Chemotherapy in Breast Cancer. , 2015, , 335-351.		0
35	Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1407-1409.	0.8	10
36	POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. Oncology, 2015, 29, 797-8, 802.	0.4	0

#	Article	IF	Citations
37	Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. Journal of the National Cancer Institute, 2013, 105, 1188-1201.	3.0	101
38	Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. Cancer Research, 2013, 73, 2943-2948.	0.4	535
39	Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 1065-1065.	0.8	0
40	Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006486-a006486.	2.9	266
41	Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1214.	3.3	34
42	TGF-Î² blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16618-16623.	3.3	287
43	Combined targeting of HER2 and VEGFR2 for effective treatment ofHER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3119-27.	3.3	131
44	A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, 1026-1026.	0.8	9
45	C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 302-307.	3.3	85
46	Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 276-280.	0.7	25
47	Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. Breast, 2011, 20, 101-110.	0.9	9
48	Normalization of the Vasculature for Treatment of Cancer and Other Diseases. Physiological Reviews, 2011, 91, 1071-1121.	13.1	1,275
49	Troponin I As a Predictor for Trastuzumab-Related Cardiotoxicity: Current Data Do Not Provide Mechanistic Insights or Allow for Incorporation Into Clinical Practice. Journal of Clinical Oncology, 2011, 29, e175-e176.	0.8	8
50	Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3725-3730.	3.3	169
51	Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 32-38.	0.7	1
52	Cancer drugs in the real world. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 1-3.	0.7	0
53	LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. The Cochrane Library, 2009, , CD004562.	1.5	53
54	Morphological changes and stress responses in neurons in cerebral cortex infiltrated by diffuse astrocytoma. Neuropathology, 2003, 23, 262-270.	0.7	24